BR112019001944A2 - métodos aperfeiçoados para produção de bibiliotecas de polinucleotídeo em células eucarióticas/vírus de vaccínia - Google Patents

métodos aperfeiçoados para produção de bibiliotecas de polinucleotídeo em células eucarióticas/vírus de vaccínia

Info

Publication number
BR112019001944A2
BR112019001944A2 BR112019001944-8A BR112019001944A BR112019001944A2 BR 112019001944 A2 BR112019001944 A2 BR 112019001944A2 BR 112019001944 A BR112019001944 A BR 112019001944A BR 112019001944 A2 BR112019001944 A2 BR 112019001944A2
Authority
BR
Brazil
Prior art keywords
vaccinia virus
bib
libraries
eukaryotic cells
improved methods
Prior art date
Application number
BR112019001944-8A
Other languages
English (en)
Inventor
Smith Ernest
Shi Shuying
Original Assignee
Vaccinex, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex, Inc. filed Critical Vaccinex, Inc.
Publication of BR112019001944A2 publication Critical patent/BR112019001944A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms

Abstract

a presente revelação fornece um método aperfeiçoado de construir uma biblioteca de polinucleotídeos de interesse em um sistema de vetor de poxvírus, por exemplo, vírus de vaccínia, onde os polinucleotídeos de interesse codificam polipeptídios de interesse. o método compreende construir a biblioteca na presença de um inibidor de montagem de poxvírus, por exemplo, rifampicina, que permite construção de bibliotecas com complexidade e diversidade maiores do que métodos anteriores.
BR112019001944-8A 2016-08-02 2017-07-31 métodos aperfeiçoados para produção de bibiliotecas de polinucleotídeo em células eucarióticas/vírus de vaccínia BR112019001944A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662370009P 2016-08-02 2016-08-02
US62/370,009 2016-08-02
PCT/US2017/044688 WO2018026715A1 (en) 2016-08-02 2017-07-31 Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells

Publications (1)

Publication Number Publication Date
BR112019001944A2 true BR112019001944A2 (pt) 2019-05-07

Family

ID=61073907

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019001944-8A BR112019001944A2 (pt) 2016-08-02 2017-07-31 métodos aperfeiçoados para produção de bibiliotecas de polinucleotídeo em células eucarióticas/vírus de vaccínia

Country Status (14)

Country Link
US (3) US20190169606A1 (pt)
EP (1) EP3494131A4 (pt)
JP (2) JP7128177B2 (pt)
KR (1) KR102449406B1 (pt)
CN (1) CN109563143A (pt)
AU (1) AU2017306062B2 (pt)
BR (1) BR112019001944A2 (pt)
CA (1) CA3032512A1 (pt)
IL (1) IL264343B1 (pt)
MX (1) MX2019001453A (pt)
RU (1) RU2747557C2 (pt)
SG (1) SG11201900595YA (pt)
WO (1) WO2018026715A1 (pt)
ZA (1) ZA201901286B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108912228B (zh) 2009-05-08 2022-03-15 瓦西尼斯公司 抗-cd100抗体和其使用方法
EA029023B1 (ru) 2011-10-11 2018-01-31 Вэксинекс, Инк. Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
MX2015017485A (es) 2013-06-25 2016-03-31 Vaccinex Inc Uso de moleculas inhibidoras de semaforina-4d en combinacion con una terapia de modulacion inmune para inhibir crecimiento tumoral y metastasis.
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
RU2759846C2 (ru) 2016-04-22 2021-11-18 Вэксинекс, Инк. Дисплей интегрального мембранного белка на внеклеточных оболочечных вирионах поксвируса
WO2018026715A1 (en) 2016-08-02 2018-02-08 Vaccinex, Inc. Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2083469T3 (es) 1989-11-22 1996-04-16 Genentech Inc Peptido asociado a una latencia y utilizaciones del mismo.
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5445953A (en) 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
WO1995030018A2 (en) 1994-04-29 1995-11-09 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
AU776865B2 (en) 1998-11-10 2004-09-23 University Of Rochester T cells specific for target antigens and methods and vaccines based thereon
US7067251B2 (en) 2000-03-28 2006-06-27 University Of Rochester Methods of directly selecting cells expressing inserts of interest
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
CN1306272C (zh) 2000-11-17 2007-03-21 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法
WO2002086096A2 (en) * 2001-01-23 2002-10-31 University Of Rochester Medical Center Methods of producing or identifying intrabodies in eukaryotic cells
US20020192675A1 (en) * 2001-02-02 2002-12-19 The University Of Rochester Methods of identifying regulator molecules
EP1413316A1 (en) 2002-09-27 2004-04-28 Bruno Robert Bifunctional conjugates or fusion proteins
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
US20050158323A1 (en) 2003-12-04 2005-07-21 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
NZ553320A (en) 2004-08-27 2011-02-25 Einstein Coll Med Ceramide derivatives as modulators of immunity and autoimmunity
US8022043B2 (en) 2004-08-27 2011-09-20 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
AU2006232310B9 (en) * 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
RU2311927C2 (ru) * 2005-08-15 2007-12-10 Федеральное государственное унитарное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" КОМБИНАТОРНАЯ ФАГМИДНАЯ БИБЛИОТЕКА ОДНОЦЕПОЧЕЧНЫХ АНТИТЕЛ ЧЕЛОВЕКА, ОБОГАЩЕННАЯ АНТИТЕЛАМИ ПРОТИВ ВИРУСА ОСПОВАКЦИНЫ, РЕКОМБИНАНТНАЯ ФАГМИДНАЯ ДНК pHEN-2A8, СОДЕРЖАЩАЯ УНИКАЛЬНЫЙ ГЕН ОДНОЦЕПОЧЕЧНОГО АНТИТЕЛА ЧЕЛОВЕКА, СПОСОБНОГО НЕЙТРАЛИЗОВАТЬ ВИРУС ОСПОВАКЦИНЫ И ВИРУС ОСПЫ КОРОВ, И ИСКУССТВЕННОЕ ОДНОЦЕПОЧЕЧНОЕ АНТИТЕЛО ЧЕЛОВЕКА 2A8, СПОСОБНОЕ НЕЙТРАЛИЗОВАТЬ ВИРУС ОСПОВАКЦИНЫ И ВИРУС ОСПЫ КОРОВ
US7858599B2 (en) 2005-12-30 2010-12-28 Hander Robert W Enhancement of urogenital function
RU2317330C2 (ru) * 2006-01-16 2008-02-20 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pcL37, КОДИРУЮЩАЯ ПОЛИПЕПТИД СО СВОЙСТВАМИ ЛЕГКОЙ ЦЕПИ АНТИТЕЛА ЧЕЛОВЕКА ПРОТИВ ВИРУСА ОСПОВАКЦИНЫ, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pcH37, КОДИРУЮЩАЯ ПОЛИПЕПТИД СО СВОЙСТВАМИ ТЯЖЕЛОЙ ЦЕПИ УКАЗАННОГО АНТИТЕЛА, И ИХ ПРИМЕНЕНИЕ
CN101020055B (zh) * 2006-02-16 2012-08-08 中国疾病预防控制中心性病艾滋病预防控制中心 基于复制型痘苗病毒载体的sars疫苗
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
WO2008100995A1 (en) 2007-02-14 2008-08-21 Vaccinex, Inc. Humanized anti-cd100 antibodies
JP5357782B2 (ja) 2007-02-21 2013-12-04 バクシネックス インコーポレーティッド 抗原負荷ＣＤ１ｄ分子によるＮＫＴ細胞活性の調節
CA2710680C (en) 2007-12-26 2018-10-16 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
US8535687B2 (en) 2008-05-28 2013-09-17 The Trustees Of The University Of Pennsylvania Smallpox DNA vaccine and the antigens therein that elicit an immune response
US20100081575A1 (en) 2008-09-22 2010-04-01 Robert Anthony Williamson Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
US9139809B2 (en) 2009-01-08 2015-09-22 Albert Einstein College Of Medicine Of Yeshiva University Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
CN108912228B (zh) 2009-05-08 2022-03-15 瓦西尼斯公司 抗-cd100抗体和其使用方法
CN103003307B (zh) 2010-03-10 2017-08-11 根马布股份公司 抗c‑MEt的单克隆抗体
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
US8206715B2 (en) 2010-05-04 2012-06-26 Five Prime Therapeutics, Inc. Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
AU2011267869A1 (en) 2010-06-14 2013-01-10 Vaccinex, Inc. Anti-VEGF antibodies and uses thereof
EP2591090A4 (en) 2010-07-07 2013-12-25 Einstein Coll Med CERAMIC LIKE GLYCOLIPIDE ASSOCIATED BACTERIAL VACCINES AND USES THEREOF
NZ608318A (en) 2010-09-02 2015-03-27 Vaccinex Inc Anti-cxcl13 antibodies and methods of using the same
JP5925768B2 (ja) 2011-05-13 2016-05-25 国立大学法人 東京医科歯科大学 骨形成促進剤
EA029023B1 (ru) 2011-10-11 2018-01-31 Вэксинекс, Инк. Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
CA2865928C (en) 2012-03-02 2021-02-16 Vaccinex, Inc. Cxcl13 antagonist for the treatment of sjogren's syndrome
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
AU2014212206B2 (en) 2013-01-31 2018-10-18 Vaccinex, Inc. Methods for increasing immunoglobulin A levels
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
MX2015017485A (es) 2013-06-25 2016-03-31 Vaccinex Inc Uso de moleculas inhibidoras de semaforina-4d en combinacion con una terapia de modulacion inmune para inhibir crecimiento tumoral y metastasis.
WO2015017852A1 (en) * 2013-08-02 2015-02-05 International Park Of Creativity Biological devices and methods of use thereof for the study and control of alzheimer's disease
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
RU2759846C2 (ru) 2016-04-22 2021-11-18 Вэксинекс, Инк. Дисплей интегрального мембранного белка на внеклеточных оболочечных вирионах поксвируса
WO2018026715A1 (en) 2016-08-02 2018-02-08 Vaccinex, Inc. Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
JP2020510845A (ja) 2017-02-22 2020-04-09 バクシネックス インコーポレーティッド 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法
EP3600419B1 (en) 2017-03-20 2023-08-09 Vaccinex, Inc. Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
KR20200004324A (ko) 2017-05-05 2020-01-13 백시넥스 인코포레이티드 인간 항-세마포린 4d 항체

Also Published As

Publication number Publication date
EP3494131A4 (en) 2020-04-15
AU2017306062A1 (en) 2019-02-07
KR102449406B1 (ko) 2022-09-29
ZA201901286B (en) 2023-05-31
JP7128177B2 (ja) 2022-08-30
CA3032512A1 (en) 2018-02-08
WO2018026715A1 (en) 2018-02-08
KR20190034304A (ko) 2019-04-01
IL264343A (en) 2019-02-28
MX2019001453A (es) 2019-06-20
CN109563143A (zh) 2019-04-02
EP3494131A1 (en) 2019-06-12
JP2022109946A (ja) 2022-07-28
JP2019524126A (ja) 2019-09-05
RU2019105695A (ru) 2020-09-07
US20190169606A1 (en) 2019-06-06
US20200299683A1 (en) 2020-09-24
US20190241889A1 (en) 2019-08-08
IL264343B1 (en) 2024-01-01
RU2747557C2 (ru) 2021-05-06
AU2017306062B2 (en) 2021-12-09
RU2019105695A3 (pt) 2020-11-02
SG11201900595YA (en) 2019-02-27
US10640765B2 (en) 2020-05-05

Similar Documents

Publication Publication Date Title
BR112019001944A2 (pt) métodos aperfeiçoados para produção de bibiliotecas de polinucleotídeo em células eucarióticas/vírus de vaccínia
CO2017011957A2 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
CO2019003154A2 (es) Anticuerpos anti-pd-1 y sus usos
BR112018013602A2 (pt) métodos e sistemas de processamento de imagem
DK3436339T3 (da) Fremgangsmåde og system til drift af én eller flere bugserbåde
IL254097B (en) Sub-pixel alignment of test to design
BR112018006811A2 (pt) compostos terapêuticos e métodos
DK3532838T3 (da) Fremgangsmåder og systemer til kromatografidataanalyse
BR112017009728A2 (pt) anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
CL2016001867A1 (es) Sistema y dispositivo para la generación de alto rendimiento de gotitas y métodos de uso combinatorios.
BR112016025347A2 (pt) método e sistema para caracterização geoquímica espacialmente resolvida
EP3195292A4 (en) Systems and methods for gimbal simulation
BR112016014387A2 (pt) Sistemas, métodos e aparelho para composição e/ou recuperação digital
IL262463B (en) Systems and methods for finding a direction using different joint matrices, for example augmented spatial
BR112018007604A2 (pt) métodos para tratar câncer usando compostos de pirimidina e piridina com atividade inibitória de btk
MX2023006229A (es) Sistemas y metodos para identificar y expresar agrupaciones de genes.
BR112018017168A2 (pt) emplastro de coloração do sangue, método e dispositivo para teste sanguíneo usando o mesmo
DK3436338T3 (da) Fremgangsmåde og system til drift af én eller flere bugserbåde
DK3405580T3 (da) Ekspressionssystem til eukaryotiske organismer
BR112018074048A2 (pt) divisória
BR112016006312A2 (pt) método e kit para determinar a presença ou ausência de staphylococcus aureus resistente à meticilina em uma amostra biológica
BR112018007517A2 (pt) métodos para tratar esclerose múltipla usando compostos de pirimidina e piridina com atividade inibidora de btk
EP3522781A4 (en) SYSTEMS AND METHODS FOR PREDICTIVE HEART VALVE SIMULATION
BR112016023586A2 (pt) resfriador de gás
EP4235179A3 (en) Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]